Oveporexton: A Promising Orexin Receptor 2 Agonist for Narcolepsy Type 1 – Results from a Phase 2 Randomized Trial

Highlights

• Oveporexton (TAK-861), an oral orexin receptor 2–selective agonist, significantly improved wakefulness and reduced cataplexy in patients with narcolepsy type 1.
• Significant improvements were observed on both the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at 8 weeks versus placebo.
• The most frequent adverse events were insomnia, urinary urgency, and urinary frequency, with no hepatotoxicity reported.
• This phase 2 trial establishes clinical proof-of-concept for direct orexin receptor 2 agonism in narcolepsy type 1.

Clinical Background and Disease Burden